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Inﬂuenza VLPs comprised of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins have
been previously used for immunological and virological studies. Here we demonstrated that inﬂuenza
VLPs can be made in Sf9 cells by using the bovine immunodeﬁciency virus gag (Bgag) protein in place of
M1. We showed that Bgag can be used to prepare VLPs for several inﬂuenza subtypes including H1N1 and
H10N8. Furthermore, by using Bgag, we prepared quadri-subtype VLPs, which co-expressed within the
VLP the four HA subtypes derived from avian-origin H5N1, H7N9, H9N2 and H10N8 viruses. VLPs showed
hemagglutination and neuraminidase activities and reacted with speciﬁc antisera. The content and co-
localization of each HA subtype within the quadri-subtype VLP were evaluated. Electron microscopy
showed that Bgag-based VLPs resembled inﬂuenza virions with the diameter of 150–200 nm. This is the
ﬁrst report of quadri-subtype design for inﬂuenza VLP and the use of Bgag for inﬂuenza VLP preparation.
& 2015 Elsevier Inc. All rights reserved.Introduction
Recombinant virus-like particles (VLPs) have been developed
for many viruses as immunological and virological reagents, as
well as safe and efﬁcacious vaccines (Kang et al., 2009; Lua et al.,
2014; Pushko et al., 2013). For example, recombinant inﬂuenza
VLPs can serve as safe reagents and vaccines for avian inﬂuenza
that cause severe respiratory diseases and can be fatal in people
(Morens and Fauci, 2012; Palese, 2006; Yen and Webster, 2009).
There is a worldwide concern that highly pathogenic avian inﬂu-
enza (HPAI) viruses of H5N1 subtype can cause a pandemic (Kang
et al., 2009; Morens and Fauci, 2012). Preparation of reagents and
vaccines from live H5N1 virus is hampered due to the biosafety
reasons. In addition to H5N1, other pathogenic avian inﬂuenza
viruses exist. The H7N9 virus caused human infections since 2013
with numerous recorded lethal cases (Chen et al., 2015; Gao et al.,
2013). Avian-origin H9N2 inﬂuenza has also been identiﬁed as a
human pathogen (Blanco et al., 2013; Pushko et al., 2005; Yen and
Webster, 2009). Furthermore, the ﬁrst human case of H10N8 virus
infection has been described (Garcia-Sastre and Schmolke, 2014;
To et al., 2014). Multiple avian inﬂuenza strains capable ofþ1 301 378 8322.
shko).reassortment and frequent genetic changes cause biosafety and
environmental concerns, as well as challenges for vaccine devel-
opment (Morens and Fauci, 2012; Palese, 2004).
Recombinant VLPs have been developed as a safe alternative to
live or inactivated viruses for immunological, virological and vac-
cine studies; including for avian subtypes of inﬂuenza (Bright
et al., 2007; Galarza et al., 2005; Kang et al., 2009; Perrone et al.,
2009; Pushko et al., 2005; Quan et al., 2010; Ross et al., 2009).
Recombinant VLPs are produced by using cell culture methods and
do not involve live inﬂuenza viruses in antigen production. In the
previous studies, VLPs were prepared by using homologous HA,
NA, and M1 proteins derived from the same virus (Perrone et al.,
2009; Pushko et al., 2010, 2005). We have also described triple-
subtype VLPs containing three subtypes of HA within the VLP
envelope along with “common” NA and M1 proteins (Pushko et al.,
2011; Tretyakova et al., 2013). However, sequence data for a virus-
speciﬁc M1 are not always readily available, especially for the
recently emerged viruses. Furthermore, vaccination with VLPs
prepared from the HA, NA and M1 can make it difﬁcult to distin-
guish vaccinated and infected individuals. VLPs were also descri-
bed, in which HA and NA were derived from the vaccine-relevant
virus, whereas M1 was derived from a heterologous inﬂuenza
virus (Liu et al., 2015) or replaced with the murine leukemia virus
gag protein (Haynes, 2009; Haynes et al., 2009) or simian/human
immunodeﬁciency virus gag protein (Guo et al., 2003). The use of
I. Tretyakova et al. / Virology 487 (2016) 163–171164gag as a VLP component can provide an M1-independent, standard
platform for VLP production and a useful vaccination marker. In
the current study, we prepared VLPs using the bovine immuno-
deﬁciency virus (BIV) gag (Bgag) protein in place of M1. We
demonstrate that inﬂuenza VLPs of H1 and H10 subtypes can be
efﬁciently prepared by using Bgag as an inner core of a VLP. Fur-
thermore, by using Bgag protein, we have prepared the ﬁrst
quadri-subtype VLPs, which co-localized H5, H7, H9, and H10
proteins derived from the four avian-origin inﬂuenza viruses.
Potential applications of Bgag-based inﬂuenza VLPs including
quadri-subtype VLPs for virological, structural and immunological
studies are discussed.
Results
Preparation of H1 PR8 VLPs using BIV gag (Bgag)
For preparation of VLPs, we used recombinant baculovirus
(rBV) expression system in Sf9 cells. Initially, we prepared VLPs by
using inﬂuenza PR8 HA and NA, as well as Bgag proteins. Inﬂuenza
PR8 virus has been often used as a reference strain in inﬂuenza
research including preparation of recombinant VLPs (Tretyakova
et al., 2013; Wang et al., 2010). In contrast, Bgag protein has not
been previously used for production of inﬂuenza VLPs. The
sequence analysis of Bgag using NCBI BLASTP software with the
default parameters did not reveal signiﬁcant homology of Bgag
with any known human pathogens. The closest similarity was only
29% with feline immunodeﬁciency virus and 26% with equine
infectious anemia virus. No similarity between Bgag and HIV gag
proteins was found. The PR8 HA and NA genes were cloned into
rBV along with the full-length Bgag gene (Fig. 1a). Alternatively,Bgag NA H1
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Fig. 1. Preparation of inﬂuenza PR8 VLPs using Bgag. (a) Recombinant baculovirus (rBV) c
genes were from A/Puerto Rico/8/1934(H1N1) (PR8) virus (ﬁlled boxes). Alternatively, NA
respectively). Bgag and inﬂuenza genes were codon-optimized for high-level express
promoters are indicated with arrows. (b) Hemagglutination assay of VLPs in the Sf9 cultu
were diluted in PBS and probed with RBC in 2-fold serial dilutions starting at 1:8 dilution
SDS-PAGE gel. Positions of HA, Bgag, and M1 are indicated. Western blot of VLPs using H
the same order as in (a); M, SeeBlue Plus2 molecular weight standard. PR8 HA is indica
indicates relative ﬂuorescent units (RFU), the X-axis shows dilution of VLPs. Dotted line
diamonds, squares, solid line, and circles, respectively. NA-negative control (PBS) is indic
co-expression of Bgag, PR8 NA and PR8 HA proteins (upper panel) or by co-expression
photungstic acid. Bar, 100 nm.the NA gene was derived from IN/05 virus. For comparison pur-
poses, we have also generated rBV with M1 gene in place of the
Bgag gene. Altogether, four rBV vectors were prepared (Fig. 1a).
Each rBV contained three genes in a tandem fashion, each gene
within its own expression cassette containing polyhedrin pro-
moter. HA activity with the turkey RBC was detected in the growth
medium of infected cells suggesting secretion of the VLPs (Fig. 1b).
All four preparations exhibited HA activity, with Bgag-containing
VLPs showing comparable or 2-fold increased HA titer as com-
pared to the M1-containing VLPs (Fig. 1b). The VLPs were har-
vested from the growth medium and concentrated and partially
puriﬁed by ultracentrifugation. Expression of PR8 HA of expected
63 kDa (565 amino acid residues) was detected by SDS-PAGE
staining and western blot using H1N1-speciﬁc antibody by wes-
tern blot (Fig. 1c). Consistent with the previous observations
(Perrone et al., 2009; Pushko et al., 2011, 2005), PR8 HA was
expressed as the full-length HA0 polypeptide, with no processing
into HA1 and HA2 detectable by SDS-PAGE or western blot. On the
stained SDS-PAGE, bands of HA, Bgag, and M1 of expected
63 kDa, 54 kDa and 28 kDa, respectively, were detected,
which migrated in the expected molecular weight range (Fig. 1c).
Consistent with previous observations, the NAwas not detected
by SDS-PAGE (Pushko et al., 2005). However, VLPs exhibited NA
enzyme activity in the functional NA assay (Fig. 1d) thus con-
ﬁrming presence of the NA protein in the VLPs. Activity of NA
enzyme was higher in the VLP preparations containing NA from
IN/5 as compared to the VLPs containing PR8 NA. Both IN/5 and
PR8 NA belong to the N1 subtype and share 83% identical amino
acid residues..
.
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onstructs for expression of PR8 VLPs in Spodoptera frugiperda (Sf9) cells. HA and NA
and M1 were from A/Indonesia/5/2005(H5N1) (IN/5) virus (shaded and dashed box,
ion in insect cells and cloned into rBV in tandem fashion as shown. Polyhedrin
re supernatants using turkey RBC. Samples 1–4 are in the same order as in (a). VLPs
. As a negative control (NC), PBS was used in place of the VLPs. (c) Coomassie stained
1-speciﬁc monoclonal antibody (MAb) is shown as bottom panel. Lanes 1–4 are in
ted with an arrow. (d) NA enzyme activity, by ﬂuorescence-based assay. The Y-axis
represents normalization line. Samples 1, 2, 3 and 4 are as in (a) and indicated with
ated with ﬁlled triangles. (e) Electron micrographs of VLPs. VLPs were prepared by
of IN/5 M1, IN/5 NA and PR8 HA (lower panel). VLPs were stained with 1% phos-
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PES membrane ﬁlters with pore sizes of 0.8, 0.45, and 0.22 μm,
with inﬂuenza antigens detected in all ﬁltrates including 0.22 μm,
suggesting VLPs size of less than 220 nm (data not shown). Finally,
the electron microscopic examination conﬁrmed presence of the
enveloped particles in the VLP preparations with characteristic HA
spikes (Fig. 1e). The diameter of Bgag-containing VLPs was
approximately 150–200 nm. This is larger than average inﬂuenza
virus of approximately 100 nm in diameter, although pleomorphic
structures of larger diameter were also reported for inﬂuenza virus
(Noda, 2011). The diameter of M1-containing VLP was approxi-
mately 120–150 nm (Fig. 1e). Taken together, these results con-
ﬁrmed formation of the PR8 VLPs by using HA, NA, and Bgag
proteins.
Preparation of H10 JX/13 VLPs
In the next experiment we tested if Bgag can be used for pre-
paration of VLP containing H10 from recent avian-origin inﬂuenza
JX/13 H10N8 virus, which caused a fatal human infection in an
elderly patient in China in 2013 and has been identiﬁed as a
pathogen of pandemic concern (Garcia-Sastre and Schmolke,
2014; To et al., 2014). The rBV was conﬁgured to express three
genes, H10, NA and Bgag (Fig. 2a, upper panel). The resulting rBV
was used to infect Sf9 cells to prepare H10 JX/13 VLPs. VLPs
comprised of H10, NA, and Bgag were harvested from 2 L of Sf9
growth medium and puriﬁed by ion exchange chromatography.
The H10 JX/13 VLPs exhibited high level of HA functional activity
(titer 1:8192 per 50 μl of 3.5 mg/ml of total protein) reﬂecting
concentration by puriﬁcation process (Fig. 2b, upper panel) and
reacted with H10-speciﬁc antibodies but not with H5-, H7-, or H9-
speciﬁc MAbs in western blot (Fig. 2c, lane 1). Both H10 and BIV
gag bands were detectable on stained SDS-PAGE (Fig. 2d, lane 1).2    3    M
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Fig. 2. Preparation of inﬂuenza H10 VLPs and quadri-subtype VLPs using Bgag. (a) Recom
quadri-subtype H5/7/9/10 VLPs (lower panel) in Sf9 cells. In H10 VLP constructs, HA was
from IN/5 (shaded box). For quadri-subtype VLPs, H5, H7, H9, and H10 HA genes were de
33982/2009(H9N2), and A/Jiangxi/IPB13a/2013(H10N8) viruses (VN/04, SH/13, HK/09, an
genes were codon-optimized for high-level expression in insect cells and cloned into r
(b) Hemagglutination assay of H10 VLPs (upper panel) and quadri-subtype VLPs (lower p
anti-H5N1, -H7N9 and H9N2 MAbs, as well as anti-H10N7 rabbit antibody. Lane 1, H10 V
SeeBlue Plus2 standard. HA is indicated with arrows. (d) Coomassie stained SDS-PAGE ge
see below). HA and Bgag are indicated. (e) NA enzyme activity, by ﬂuorescence-based a
quadri-subtype VLPs are indicated with solid squares and triangles, respectively. Negativ
The NA enzymatic activity was measured in relative ﬂuorescent units (RFU) as indicateFunctional NA enzyme activity was also detected at a high level
(Fig. 2e). By electron microscopy of H10 VLPs, enveloped particles
of approximately 150–180 nm in diameter were observed in the
H10 VLP preparation (Fig. 3a).
Preparation of quadri-subtype H5/7/9/10 VLPs
Previously, VLPs were conﬁgured to contain three HA subtypes
along with NA and M1 within the triple-subtype VLP structures,
which were used in vaccine studies. Such triple-subtype VLPs
elicited protective immunity in ferrets against challenge with
corresponding inﬂuenza virus subtypes (Pushko et al., 2013; Tre-
tyakova et al., 2013). However, it is not known if Bgag can be used
for preparation of such multi-subtype VLPs. In the next experi-
ment, we evaluated Bgag for expression of the ﬁrst quadri-subtype
VLPs containing four HA subtypes. In order to prepare quadri-
subtype VLPs, the HA proteins were derived from the four avian-
origin inﬂuenza viruses, subtypes H5N1, H7N9, H9N2, and H10N8.
The HPAI H5N1 virus, VN/04 of clade 1, was originally isolated
from a fatal human case (Maines et al., 2005). The H7N9 virus, SH/
13, was isolated from a hospitalized patient with a fatal disease
(Gao et al., 2013). The H9N2 virus, HK/09 of G1 clade, was ori-
ginally isolated from a nasopharyngeal aspirate of an adult patient
(Cheng, 2010). The H10N8 virus JX/13 was described above.
In order to prepare quadri-subtype VLPs, an rBV vector was
conﬁgured to co-express H10 (JX/13), H5 (VN/05), H7 (SH/13), and
H9 (HK/09) HA proteins along with NA and Bgag proteins (Fig. 2a,
bottom panel). Previously, we prepared triple-subtype VLPs using
M1 protein (Pushko et al., 2011). In this study, we focused on Bgag
as a VLP component due to its potential advantages and did not
use M1 for VLP preparation. The H5, H7, H9, and H10 genes
encoded polypeptides of 568 aa, 560 aa, 560 aa, and 561 aa in
length with predicted average molecular masses of 64.5 kDa,1     2   M    
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Fig. 3. Negative stain transmission electron microscopy of H10 VLPs and quadri-subtype H5/7/9/10 VLPs (a, b); and stability of expression of quadri-subtype VLPs (c). (a, b)
Puriﬁed H10 VLP (a) and quadri-subtype H5/7/9/10 VLP (b) were stained with 1% phosphotungstic acid. Bar, 100 nm. (c) Hemagglutination assay of quadri-subtype VLPs
prepared in Sf9 cells infected with rBV from passages P1 through P5. VLPs were harvested from rBV-infected S9 cell supernatants, ﬁltered through 0.22 μm pore size
membrane, concentrated 100-fold by ultracentrifugation and resuspended in PBS. HA assay was performed using turkey RBC starting at VLP dilution 1:128. As negative
control (NC), PBS was used in place of the VLPs.
I. Tretyakova et al. / Virology 487 (2016) 163–17116662.1 kDa, 62.9 kDa, and 62.3 kDa, respectively. The NA was derived
from IN/05 virus. For preparation of VLPs, Sf9 cells were infected
with rBV at MOI of 3.0 to allow expression of H5, H7, H9, H10, NA,
and Bgag genes. The VLPs were harvested from culture super-
natant on day 3 post-infection, clariﬁed by centrifugation and
0.22 μm ﬁltration and puriﬁed by ion exchange chromatography.
The functional ability of H5/H7/H9/H10 VLPs to agglutinate
turkey RBCs was conﬁrmed by hemagglutination assay using tur-
key RBCs. The hemagglutination activity at the titer of 1:8192 per
50 μl of puriﬁed VLPs (3.5 mg/ml total protein) conﬁrmed that the
incorporated HA proteins retained their functional stability and
RBC binding activities (Fig. 2b, bottom panel). The presence of
Bgag and of HA proteins was further conﬁrmed by western blot
using antibodies speciﬁc for each HA subtype and by stained SDS-
PAGE (Fig. 2c and d, lane 2). VLP preparation reacted with H5-,
H7-, H9-, and H10-speciﬁc antibodies (see also Fig. 4 below). The
HAs within VLPs represented uncleaved HA0 polypeptides of
approximately 62–64 kDa. A band of approximately 55 kDa cor-
responding to Bgag protein was detected by SDS-PAGE (Fig. 2d,
lane 2). No considerable cell- or baculovirus-derived impurities
were detected in the puriﬁed VLP preparations. In order to conﬁrm
NA enzyme activity, we conducted NA functional enzyme assay.
The NA enzymatic activity of quadri-subtype VLPs was conﬁrmedby using ﬂuorescence-based inﬂuenza NA assay (Fig. 2e). Notably,
the activity of NA was higher in JX/13 H10 VLPs as compared to the
H5/H7/H9/H10 VLPs suggesting that NA may be expressed at a
lower level in the quadri-HA VLPs due to the promoter dilution
effect resulting from co-expression of multiple genes in the H5/
H7/H9/H10 VLPs. Taken together, the results suggested that in
quadri-HA VLPs, all four HA subtypes, as well as NA and Bgag
proteins were co-puriﬁed from Sf9 cells by chromatography, as
expected for inﬂuenza VLPs.
The size and morphology of quadri-subtype H5/H7/H9/H10
VLPs were further examined by negative-staining transmission
electron microscopy. The H5/H7/H9/H10 VLPs were identiﬁed as
largely spherical, inﬂuenza-like, pleomorphic, enveloped particles
approximately 150–200 nm in diameter and containing typical
inﬂuenza HA spikes protruding from the VLP envelope (Fig. 3b).
Stability of expression of quadri-HA VLPs
In order to test stability of rBV vector expressing six VLP-relevant
genes, the rBV was consecutively passed ﬁve times in Sf9 cells at MOI
of 0.01. The resulting progeny rBV (passages P1 to P5) were used
to infect fresh Sf9 cells as described above to generate VLPs. In this
case, the VLPs were partially puriﬁed and concentrated 100-fold
from the Sf9 culture supernatants by ultracentrifugation, and the
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Fig. 4. Co-localization of HA subtypes and quantitation of HA proteins within quadri-subtype H5/7/9/10 VLPs. (a) Co-localization of HA subtypes within quadri-subtype VLP,
by immunopreciptation using H5-speciﬁc MAb followed by western blot using H5-, H7- and H9-speciﬁc MAbs and H10-speciﬁc rabbit antiserum. Samples 1–5 represent rH5,
rH7, rH9, rH10 and quadri-subtype VLP antigens, respectively. C, negative control for immunopreciptation (PBST buffer only). (b) Quantitation of HA subtypes within quadri-
subtype VLP by semi-quantitative western blot. Upper panel, Coomassie blue-stained SDS-PAGE for quantitation of rH5, rH7, rH9, rH10 and H5/7/9/10 VLP by densitometry.
Band of 54 kDa in lane 5 represents Coomassie blue-stained Bgag protein. Lower panels, western blots with indicated antibodies. Content of each HA subtype within the VLP
was determined using western blot by comparing band intensity in the VLP lane to the band intensity of known amount of corresponding rHA reference antigen. Samples 1–
7 represent rH5, rH7, rH9, rH10, quadri-subtype H5/7/9/10 VLP, 0.2 mg/ml BSA (5 μl), and 0.1 mg/ml BSA (5 μl), respectively. M, See Blue Plus2 protein molecular weight
ladder (Life Technologies).
Table 1
HA content in the quadri-subtype VLPsa.
HA antigen HA content, μg/mlþSDb HA content, %
H5 298.5477.4 23.8
H7 286.6743.8 22.8
H9 428.879.6 34.2
H10 241.175.4 19.2
a By SDS-PAGE densitometry and semi-quantitative western blot.
b SD, standard deviation.
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key RBC. The HA activity was comparable in the VLP preparations
prepared using the rBVs from P1 through P5 passages (Fig. 3c). No
apparent reduction of HA activity was detected in VLPs from P1 rBV
suggesting stability of expression of quadri-subtype VLP for at least
ﬁve rBV passages.
Co-localization of H5, H7, H9 and H10 subtypes within quadri-HA
VLPs
To determine if H5, H7, H9 and H10 subtypes are co-localized
within the VLPs, we performed immunoprecipitation experiment
(Fig. 4a). Puriﬁed quadri-HA VLPs, as well as puriﬁed full-length
individual rH5, rH7, rH9 and rH10 HA proteins were immunopreci-
pitated using H5-speciﬁc MAb. Previously, we have shown that the
full-length puriﬁed rHA forms subviral particles of approximately
20 nm diameter retaining hemagglutination function suggesting
correct protein folding and conformation (Pushko et al., 2015). In the
cases of rH5, rH7, rH9, and rH10 HA proteins, only rH5 is expected to
immunoprecipitate with the H5-speciﬁc MAb. However, if the HA
subtypes are co-localized within the quadri-HA VLPs, immunopre-
cipitation of VLPs with H5-speciﬁc MAb is expected to co-precipitate
H5 with the other HA subtypes within the VLPs. The HA proteins
within the H5-immunoprecipitated complexes were detected by
western blot using a panel of H5-, H7-, H9- and H10-speciﬁc anti-
bodies (Fig. 4a). As expected, when H5 MAb-immunoprecipitated
complexes were probed in western blot using anti-H5 MAb, only rH5antigen (lane 1) and quadri-HA VLP (lane 5) showed positive reac-
tions suggesting successful immunoprecipitation of rH5 and VLP
(Fig. 4a, upper panel). In contrast, the rH7 (lane 2), rH9 (lane 3) or
rH10 (lane 4) could not be precipitated by H5 MAb, as immunopre-
cipated complexes did not show in western blot any reaction with
H7-, H9, or H10-speciﬁc antisera (Fig. 4a). However, the H5-
immunoprecipited complexes containing quadri-HA VLP (lane 5)
showed positive reactions when probed with anti-H5, -H7, -H9, and
-H10 antibodies. This result suggested that the H5 MAb co-
immunoprecipitated with other HA subtypes thus conﬁrming co-
localization of HA subtypes within the quadri-subtype VLP.
Quantitation of HA subtypes within quadri-HA VLPs
To determine the content of each HA subtype in the quadri-
subtype VLP, we used semi-quantitative western blot with
subtype-speciﬁc anti-H5, -H7 and -H9 MAbs and anti-H10 anti-
bodies. Initially, puriﬁed rH5, rH7, rH9 and rH10 standards were
quantitated by densitometry of stained SDS-PAGE using reference
BSA protein as a standard (Fig. 4b, upper panel). The antibodies
reacted speciﬁcally in western blot with the corresponding full-
length rH5, rH7, rH9 and rH10 proteins. To quantitate each HA
subtype within the quadri-HA VLPs by western blot with each
antibody, we compared band intensity in the VLPs to that of the
corresponding rHA of known concentration. For example, by using
western blot with anti-H5 MAb, the content of H5 in the VLP was
determined by densitometry by comparing the intensity of the H5
I. Tretyakova et al. / Virology 487 (2016) 163–171168band in the VLPs to that in the rH5 (Fig. 4b). Although western blot
is a semi-quantitative assay, because concentration of rH5 refer-
ence was known, content of H5 protein in the VLP could be cal-
culated. Similarly, contents of H7, H9, and H10 within quadri-VLP
were determined (Fig. 4b, Table 1). With availability of validated
reagents, quantitation can be further improved. In summary, the
percentages of H5, H7, H9, and H10 in the quadri-HA VLP were
calculated as approximately 23.8%, 22.9%, 34.2%, and 19.2%,
respectively.
Discussion
Recombinant VLPs have been used in immunological, structural
and virus research including studying virus–host cell interactions
(Charpilienne et al., 2002), as surrogates in environmental per-
sistence and inactivation studies (Caballero et al., 2004) and as
vehicles to deliver epitopes and genes (Panda et al., 2015; Pushko
et al., 2013). Furthermore, VLPs have been often evaluated as safe
and effective vaccines for many viruses including inﬂuenza
(Kushnir et al., 2012; Pushko et al., 2013). Inﬂuenza VLPs com-
prised of HA, NA, and M1 proteins (Pushko et al., 2005) elicited
highly efﬁcient protective immune responses, which in some cases
exceeded immune responses elicited by traditional inﬂuenza
vaccines (Bright et al., 2007; Pushko et al., 2007). The virus-like
morphology and high immunogenicity of inﬂuenza VLP vaccines
resulted from the organization of HA into regular, highly repeated
patterns resembling viral structures (Kang et al., 2009; Pushko
et al., 2013). Preparation of inﬂuenza VLP often involved cloning of
three strain-speciﬁc genes, HA, NA, and M1, into an rBV vector in
order to generate VLPs (Perrone et al., 2009; Pushko et al., 2010,
2005, 2007). However, the complete sequences of all genes
including NA and M1 are not always available, especially for the
newly emerging viruses. Therefore, in some studies, a “generic”
M1 was used for VLP production process, while HA and NA were
derived from the vaccine-relevant strain of interest (Liu et al.,
2015). In other VLP designs, retrovirus gag protein derived from
murine leukemia virus or from SIV/HIV has been used in place of
M1 protein (Guo et al., 2003; Haynes et al., 2009).
To prepare inﬂuenza VLPs, in this study we used BIV gag (Bgag)
in place of M1 as a standard inner core protein of inﬂuenza VLP.
BIV belongs to the Lentivirus genus of the Retroviridae family of
viruses. BIV has been previously used to develop genetic vectors
(Luo et al., 2012). However, the use of Bgag for VLP preparation
including inﬂuenza VLPs has not yet been described. In our
experiments, HA, NA, and Bgag genes were co-expressed from a
single rBV expression vector for VLP production. The advantage of
a single rBV expression vector containing multiple genes is a
uniform co-expression of all VLP-relevant genes in the infected Sf9
cell. Furthermore, the approach allows cloning of strain-speciﬁc
HA gene into a prefabricated rBV transfer vector containing
“standard” Bgag and NA genes. This facilitates baculovirus vector
preparation and accelerates the VLP preparation process. Finally,
BIV is not a human pathogen. No similarity between BIV and
human retroviral gag proteins was found. Therefore, the use of
Bgag has advantage for human applications such as development
of diagnostics or vaccines. Furthermore, the Bgag as a vaccine
component can be a useful marker if the need arises to conﬁrm the
fact of vaccination. This can be especially important for veterinary
applications, in which differentiation of infected from vaccinated
animals (DIVA) is important (Rahn et al., 2015; Suarez, 2012).
We showed that Bgag can be used in place of M1 to prepare VLP
containing PR8 H1 or recent inﬂuenza H10 proteins. Such VLPs
exhibited functional hemagglutination and NA enzyme activities.
Notably, the 150–180 nm average diameter of inﬂuenza VLPs con-
taining Bgag, appeared larger than that of the M1-containing VLPs
(120–150 nm). It is plausible to suggest that due to the largersurface area of Bgag-based VLPs they can accommodate more HA
trimers as compared to the smaller M1-based VLPs. It has been
estimated that a spherical virion of average diameter 120 nm has
375 spikes (Harris et al., 2006). Assuming equal distribution of
trimers, calculations show that a particle with the diameter of
180 nm would accommodate approximately 800 spikes. Previously,
VLPs containing HA proteins from three viruses have been reported.
Electron microscopic examination showed that VLPs co-localize
multiple subtypes of HA within the same particle, thus acquiring
capability to protect against multiple inﬂuenza viruses following
vaccination (Pushko et al., 2011; Tretyakova et al., 2013). Multi-
subtype VLPs can also represent novel multi-speciﬁc inﬂuenza diag-
nostic reagents or vaccines, which are designed to elicit speciﬁc
immunity to several inﬂuenza virus strains. Here we describe for the
ﬁrst time a recombinant quadri-subtype VLP design, in which four
avian-origin HA subtypes were co-expressed within VLPs. Quadri-
subtype VLPs were prepared in a single manufacturing cycle and can
potentially be used as broadly-speciﬁc diagnostic reagent to detect
antibodies to avian inﬂuenza viruses known to infect people. Avian
inﬂuenza viruses of H5, H7, H9, and H10 subtypes have been iden-
tiﬁed as pathogens of pandemic concern (Belser et al., 2008; Garcia-
Sastre and Schmolke, 2014; Palese, 2004; Pappas et al., 2007; WHO,
2013). In addition to the potential of causing lethal human disease,
avian inﬂuenza can cause epizootics in the agricultural poultry spe-
cies that can threaten food supply and safety. Epizootics can also
result in the shortage of egg production for consumption, as well as
for manufacturing of vaccines. Eggs are used worldwide for vaccine
manufacturing including vaccines against inﬂuenza, yellow fever,
mumps and measles viruses. Thus, quadri-HA VLPs can also be con-
sidered as a vaccine against multiple potentially pandemic or epi-
zootic inﬂuenza strains. To enhance pandemic preparedness, inacti-
vated H5N1 vaccines have been approved (O'Neill and Donis, 2009)
including cell culture-derived inﬂuenza vaccines. Both the VN/04
(H5N1) and HK/09 (H9N2) viruses are on the list of candidate vac-
cines recommended by the World Health Organization (WHO) in
2012 for pandemic preparedness (WHO, 2012a). However, although
promising experimental vaccines have been reported (Chen et al.,
2014; Kong et al., 2015; Smith et al., 2013; Tretyakova et al., 2013;
Wohlbold et al., 2015), currently there are no approved human vac-
cines for H7, H9 or H10 subtypes (WHO, 2012a).
Current strategies to vaccination against multiple inﬂuenza viru-
ses include blended vaccines, as well as experimental universal
vaccine approaches involving consensus sequences of HA protein or
conserved inﬂuenza epitopes, for example stem region of HA or the
ectodomain of M2 ion channel protein (Deng et al., 2015; Denis et al.,
2008; Ebrahimi and Tebianian, 2011; Impagliazzo et al., 2015; Lee et
al., 2015; Pica and Palese, 2013; Rao et al., 2010; Schotsaert et al.,
2009; Wang and Palese, 2009; Wei et al., 2010). Our results suggest
that quadri-subtype VLPs can be considered as a vaccination
approach. However, evaluation of immunogenicity and efﬁcacy
in vivo is needed, which was out of scope of this study. Additional
research is also needed to optimize yields of VLPs, to compare quadri-
subtype VLPs to blended VLP formulation, to assess the role of gly-
cosylation in insect cells and to determine if distinct HA subtypes
form homo- or heterotrimers on the surface of the VLPs. Previous
studies suggested that mixed trimers are not formed between the
HAs of distinct subtypes and that incorrectly folded HAmolecules are
excluded during intracellular transport and exocytosis (Boulay et al.,
1988; Chao, 1992). For the HA quantitation purpose, the single radial
immunodiffusion (SRID) test recommended by the Center for Biolo-
gics Evaluation and Research (CBER) can be employed. However,
standardized reagents for avian-origin inﬂuenza strains are not yet
readily available. In our semi-quantitative experiments we observed
that content of distinct HA subtypes in the quadri-subtype VLP varies
from 19.2% to 34.2% of the total HA, potentially reﬂecting differences
in quantitation method or differences in the expression of distinct HA
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regulated by the protein engineering methods. For example, incor-
poration of HIV env protein into VLPs has been improved more than
10-fold by the rational design of env (Wang et al., 2007). In summary,
the current study shows that quadri-subtype H5/H7/H9/H10 VLPs
prepared using Bgag can be considered for the structural and diag-
nostic studies, as well as an option for the development of a pre-
pandemic inﬂuenza vaccine. In the case of an outbreak involving H5,
H7, H9, or H10 avian inﬂuenza viruses, quadri-subtype vaccine could
be used as a ﬁrst line of defense during the time period that is
required to make a speciﬁc vaccine against a culprit virus. If proven
useful as immunological reagents or vaccines, quadri-subtype VLP
approach can also be applicable to prepare VLPs containing HA
antigens from other inﬂuenza viruses including seasonal strains.
Materials and methods
Viruses, plasmids and cells
BIV R-29 gag (Bgag) protein sequence was obtained from
GenBank, accession number AAA42763. Inﬂuenza M1 protein
sequence, GenBank protein accession number ABI36004, was
derived from A/Indonesia/5/2005(H5N1) virus, further designated
IN/05. Inﬂuenza HA gene sequences were derived from A/Puerto
Rico/8/1934(H1N1), A/VietNam/1203/2004(H5N1), A/Shanghai/2/
2013(H7N9), A/Hong Kong/33982/2009(H9N2), and A/Jiangxi/
IPB13a/2013 (H10N8) viruses, further designated PR8, VN/04, SH/
13, HK/09, and JX/13 respectively. The sequences for HA proteins
were obtained from the GenBank protein accession numbers
ABP64731, AAW80717, YP_009118475, AGO17847, and AHK10762,
respectively. Inﬂuenza NA proteins were from PR8, accession
number ABD77678, and from IN/05, accession number ABW06107.
Based on the indicated protein sequences, the genes were
codon-optimized for high-level expression in Spodoptera frugi-
perda (Sf9) cells (Life Technologies, Carlsbad, CA) and synthesized
biochemically (Genscript, Piscataway, NJ). In order to generate
VLPs, inﬂuenza HA, NA, and Bgag genes were cloned in tandem
fashion into the baculovirus transfer vector plasmid, each gene
within its own transcriptional cassette that included a polyhedrin
promoter upstream from each gene, essentially as described
elsewhere (Pushko et al., 2005). For control purposes, M1 derived
from IN/5 virus was used in place of the Bgag. To prepare the
quadri-subtype pandemic VLPs, the full-length HA genes derived
from the four indicated subtypes, as well as IN/05 NA and Bgag
genes were cloned into the baculovirus transfer vector resulting in
the plasmid containing six VLP-relevant genes. For characteriza-
tion and quantitation of HA proteins in the VLPs, we also prepared
constructs for expression of individual HA genes from each indi-
cated inﬂuenza subtype. Each gene (H5, H7, H9 or H10) was cloned
into baculovirus pFastBac1-derived transfer vector downstream
from a polyhedrin promoter.
Recombinant baculoviruses (rBV) expressing indicated genes
were generated in S. frugiperda (Sf9) cells using a Bac-to-Bac
baculovirus expression system (Life Technologies). Brieﬂy, bac-
mids containing the full-length infectious baculovirus DNA with
recombinant genes were isolated from DH10Bac Escherichia coli
and used to transfect Sf9 cells to generate rBV. Preparations of rBV
were subsequently plaque-puriﬁed. The titers of rBV preparations
were determined by Virus Counter 2100 instrument (ViroCyt,
Boulder, CO) and by standard plaque assay in Sf9 cells. For rBV
genetic stability studies, rBV was passed in Sf9 cells ﬁve times. The
rBV stocks were prepared by infecting Sf9 cells at a multiplicity of
infection (MOI) of 0.01.
Preparation of inﬂuenza VLPs
Sf9 cells were maintained as suspension cultures in SF900II-SFM
insect serum free medium (Life Technologies) at 27 °C. For productionof VLPs, Sf9 cells (2106 cells/ml) were infected at a MOI of 3.0 for
72 h with rBV expressing indicated genes. VLPs were harvested from
the growth medium supernatant, clariﬁed using centrifugation and
0.2 μm ﬁltration, and then concentrated and puriﬁed by using a 20%
(w/v) sucrose step gradient in phosphate buffered saline (PBS).
Alternatively, VLPs were puriﬁed by ion exchange chromatography as
described elsewhere (Liu et al., 2015).
The size of the VLPs was initially estimated by ﬁltration using
polyethersulfone (PES) membrane ﬁlters with pore sizes of 0.8, 0.45,
and 0.22 μm, followed by the ﬁltrate analysis using SDS-PAGE, wes-
tern blot, and hemagglutination assay. The SDS-PAGE was done in 4–
12% polyacrylamide gels (Life Technologies) followed by staining with
GelCode Blue stain (Pierce, Rockford, IL). Western blots were carried
out by using speciﬁc primary antibodies followed by the alkaline
phosphatase-conjugated goat anti-species IgG (HþL). As primary
antibodies, we used the following: anti-HA Clade 1 Inﬂuenza A H1N1
Viruses IT-003-001M14 mouse IgG1 monoclonal antibody (MAb),
clone 15B7; anti-H5(H5N1) IT-003-005M6 mouse IgG2a MAb, clone
268D8; anti-HA(H7N9)(A/Shanghai/1/2013) IT-003-0073M1 mouse
IgG1 MAb, clone 9B12; anti-H9(A/Hong Kong/33982/2009)(H9N2) IT-
003-0094M5 mouse IgG1 MAb, clone 17D8; and anti-H10(A/blue-
winged teal/Louisiana/Sg-00073/07(H10N7)) IT-003-034 rabbit poly-
clonal antibody (Immune Technology, New York, NY). The bands were
visualized by using alkaline phosphatase labeled secondary antibody
and stained with BCIP/NBT substrate (KPL, Gaithersburg, MD).
Preparation of recombinant hemagglutinin (rHA) H5, H7, H9, H10
proteins
To prepare the full-length rHA proteins of indicated subtypes, Sf9
cells were infected at MOI of 3.0 with appropriate recombinant
baculovirus containing either H5 (VN/04), H7 (SH/13), H9 (HK/09) or
H10 (JX/13 gene). Infected Sf9 cells were incubated for 72 h to allow
expression of rHA protein. After incubation, the cells were harvested
by centrifugation, followed by the lysis in a hypotonic buffer con-
taining a mild nonionic surfactant Tergitol™ NP-9 (Pushko et al.,
2015). The full-length rHA proteins were then puriﬁed and con-
centrated by lectin afﬁnity chromatography (Pushko et al., 2015).
Each rHA protein was subsequently dialyzed against Tris-buffered
saline containing 0.01% nonionic surfactant Polysorbate 80 (PS80),
ﬁlter sterilized and stored at 80 °C until use. Proteins were quan-
titated by Qubit 2.0 ﬂuorometer (Life Technologies).
Hemagglutination and neuraminidase enzyme functional assays
For hemagglutination assay, VLPs were serially diluted in PBS at
2-fold increments in 50 μl volume in a 96-well plate. To each VLP
dilution, 50 μl of 1% turkey red blood cell (RBC) working solution
was added. Turkey RBC are recommended by the WHO as a
reagent for animal inﬂuenza diagnosis and surveillance (WHO,
2012b). Mixtures of VLPs and RBCs were gently agitated and the
plate was incubated at room temperature for 30–60 min before
examination. Negative hemagglutination results appeared as dots
in the center of the wells. The titer was calculated as the highest
dilution factor that produced a positive reading.
The functional neuraminidase enzymatic activity was deter-
mined by using a ﬂuorescence-based NA assay (NA-Fluor, Life
Technologies) with methyl umbelliferone N-acetyl neuraminic
acid as a substrate according to manufacturer's instructions.
Diluent (saline or PBS) was used as a negative control. A standard
curve to identify an RFU value within the linear range of ﬂuores-
cence detection was generated using 4-methylumbelliferone
sodium salt (Sigma, St. Louis, MO).
Immunoprecipitation of VLPs
Immunoprecipitation was done using SureBeads™ magnetic
beads (BioRad, Hercules, CA) and anti-H5(H5N1) MAb. Brieﬂy, 50 μl
of SureBeads were washed 3 times with PBS buffer containing 0.1%
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250 μl PBST and 1 μg of anti-H5(H5N1) MAbwas added to the beads.
The antibody was allowed to bind to the beads on a rotator at 20 °C
for 1 h. The beads were washed from unbound antibody 3 times
with PBST, and subsequently incubated with 90 ng of quadri-subtype
H5/H7/H9/H10 VLP in a total volume of 250 μl for another 1 h on a
rotator at 20 °C. As controls for immunoprecipitation, puriﬁed rH5,
rH7, rH9 and rH10 were used (15 ng/reaction). After antigen binding,
beads were washed 3 times with PBST. The bound antigen was
eluted by adding 80 μl of Laemmli buffer and incubated for 10 min at
70 °C. The eluates were separated from the beads and analyzed by
SDS-PAGE and western blot using appropriate antibodies.
Quantitation of HA in rHA and VLPs
Total protein concentration in the VLP or in the rHA preparations
was determined by using a Qubit 2.0 ﬂuorometric method (Life
Technologies). The HA content was determined by densitometry of
stained SDS-PAGE gels by using known amounts of BSA standard (Life
Technologies). Brieﬂy, the VLPs, rHA and BSA samples were prepared
in Laemmli buffer. Proteins (0.3 mg total protein) were separated by
SDS-PAGE under reducing condition and stained as described above.
Gel images were recorded using GeneGenius Bio-Imaging System
(Syngene, Cambridge, U.K.) and analyzed using NIH ImageJ software
(http://imagej.nih.gov/ij/). A linear standard curve for the BSA stan-
dards was generated and the amount of HA was determined. The
value was adjusted according to the dilution factor and the sample
volume to obtain concentration of the HA in the sample.
To determine the content of each HA subtype in the quadri-HA
VLP, the HA content in the VLP was compared to that of the puriﬁed
rH5, rH7, rH9 and rH10 HA proteins in a semi-quantitative western
blot by using H5, H7, or H9-speciﬁc MAbs, as well as H10-speciﬁc
rabbit polyclonal antibody. Since the concentration of each individual
rHA protein was known, the concentration of the same HA subtype
in the quadri-subtype VLP was determined using densitometry
analysis by comparing HA band intensities in the individual HA and
in the quadri-subtype VLPs.
Transmission electron microscopy (TEM) of VLPs
VLP samples were adsorbed onto a freshly discharged 400
mesh carbon parlodion-coated copper grids (Poly-Sciences, War-
rington, PA). The grids were rinsed with buffer containing 20 mM
Tris, pH 7.4, and 120 mM KCl and negatively stained with 1%
phosphotungstic acid, then dried by aspiration. VLPs were visua-
lized on a Hitachi H-7600 transmission electron microscope
(Hitachi High Technologies America, Schaumburg, IL) operating at
80 kV and digitally captured with a CCD camera at 1 k1 k
resolution (Advanced Microscopy Techniques Corp., Danvers, MA).Acknowledgments
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